Actively Recruiting
Quantitative Susceptibility Mapping for Lesion Differentiation in Aging Multiple Sclerosis
Led by Oslo University Hospital · Updated on 2026-06-01
1000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating an advanced MRI method called Quantitative Susceptibility Mapping (QSM) to better distinguish white matter lesions in people aged 50 to 70 with multiple sclerosis (MS). In older adults with MS, white matter changes seen on MRI may be caused by MS or other conditions like age-related changes or chronic small vessel disease, which can look similar on standard MRI scans. This study aims to see if QSM can improve the accuracy of lesion characterization and clinical interpretation of MRI results in this population. Participants include two groups: individuals with MS aged 50-70 undergoing routine clinical MRI with an added QSM sequence, and an age-comparable group with cerebral small vessel disease (cSVD) who will have a single MRI including QSM. The MS group will have longitudinal follow-up with repeated MRI and clinical assessments, while the cSVD group will have one study visit. Both groups will have cognitive and physical function tests alongside MRI exams. During the study, participants will undergo standard clinical MRI scans plus the QSM sequence, along with brief tests of cognitive processing speed, executive function, and physical abilities. Researchers will analyze lesion susceptibility characteristics from the MRI and explore links between these measures and clinical function. The main outcome is lesion-level quantitative susceptibility within white matter lesions at baseline. Follow-up assessments in the MS group will track changes in lesions and clinical scores through December 2030.
CONDITIONS
Brief Title
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50-70 years
- Clinically confirmed diagnosis of multiple sclerosis
- Participation in the AgeMS study at Oslo University Hospital
- Age 50-80 years (for cerebral small vessel disease control group)
- Radiological evidence of hypertensive small vessel disease on MRI (for control group)
- Good clinical recovery following transient ischemic attack, minor stroke, or stroke mimic diagnosis (for control group)
You will not qualify if you...
- Contraindications to MRI
- Severe psychiatric comorbidity
- Major functional disability unrelated to multiple sclerosis or cerebral small vessel disease
- Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0 (for control group)
- Genetic or inflammatory vasculopathies (for control group)
- Persistent neurological deficits (for control group)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single MRI session for cSVD cohort; baseline and repeated assessments through December 2030 for MS cohort
Participants receive MRI scans including standard sequences and an additional QSM acquisition, along with standardized clinical assessments to evaluate white matter lesions and clinical function.
1 MRI session for cSVD cohort; baseline and repeated clinical and MRI assessments for MS cohort
Duration - Baseline through December 2030
Participants with multiple sclerosis are followed longitudinally through routine clinical MRI and clinical assessments to monitor lesion changes and clinical function over time.
Repeated clinical and MRI assessments for MS cohort
Trial Site Locations
Total: 1 location
1
Oslo University Hospital
Oslo, Oslo, Norway, 0450
Actively Recruiting
Research Team
A
Anna Therese Bjerkreim, MD PhD
L
Lars Skattebøl, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here